RECCHIUTI, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 2.713
EU - Europa 1.624
AS - Asia 1.622
SA - Sud America 184
AF - Africa 39
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.192
Nazione #
US - Stati Uniti d'America 2.630
SG - Singapore 677
CN - Cina 450
IT - Italia 329
IE - Irlanda 249
SE - Svezia 221
UA - Ucraina 186
BR - Brasile 157
GB - Regno Unito 155
TR - Turchia 145
DE - Germania 132
VN - Vietnam 109
FR - Francia 104
IN - India 102
FI - Finlandia 54
CA - Canada 50
RU - Federazione Russa 48
AT - Austria 46
HK - Hong Kong 32
PL - Polonia 24
JP - Giappone 20
KR - Corea 19
NL - Olanda 16
MX - Messico 15
ZA - Sudafrica 15
AR - Argentina 14
ES - Italia 14
BD - Bangladesh 12
BE - Belgio 12
BZ - Belize 12
EG - Egitto 11
AU - Australia 9
IR - Iran 9
IL - Israele 8
LT - Lituania 8
IQ - Iraq 7
PK - Pakistan 7
CZ - Repubblica Ceca 6
CL - Cile 4
KE - Kenya 4
MA - Marocco 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CO - Colombia 3
EC - Ecuador 3
HR - Croazia 3
ID - Indonesia 3
PT - Portogallo 3
SA - Arabia Saudita 3
AL - Albania 2
BY - Bielorussia 2
EE - Estonia 2
GE - Georgia 2
LB - Libano 2
PA - Panama 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
SN - Senegal 2
UZ - Uzbekistan 2
BH - Bahrain 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EU - Europa 1
GA - Gabon 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
JO - Giordania 1
NI - Nicaragua 1
NO - Norvegia 1
PH - Filippine 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 6.192
Città #
Singapore 507
Chandler 366
Dublin 247
Jacksonville 229
Ashburn 208
Dallas 126
New York 126
Beijing 123
Princeton 110
Dearborn 94
Southend 88
Izmir 77
Ann Arbor 74
The Dalles 69
Wilmington 66
Los Angeles 64
Nanjing 62
Santa Clara 61
Boardman 56
Pescara 55
Chieti 43
Altamura 41
Rome 36
Houston 35
Vienna 35
Tongling 34
Ho Chi Minh City 32
Woodbridge 32
Cambridge 28
Hefei 26
Montreal 26
Redondo Beach 26
Washington 25
Buffalo 24
Hanoi 24
Augusta 23
Munich 23
Nuremberg 23
San Mateo 22
Brooklyn 21
Nanchang 21
Hong Kong 20
São Paulo 19
Warsaw 19
Dong Ket 17
Helsinki 17
Tokyo 17
Toronto 15
Denver 14
Brussels 12
Central 12
Falls Church 12
Johannesburg 12
Naples 12
Ancona 11
Chennai 11
Frankfurt am Main 11
Seattle 11
Shenyang 11
Ankara 10
Jiaxing 10
Lappeenranta 10
Milan 10
Phoenix 10
Tianjin 10
Cairo 9
Orem 9
Seoul 9
Ascoli Piceno 8
Boston 8
Chicago 8
Poplar 8
San Francisco 8
Amsterdam 7
Kunming 7
New Delhi 7
Shanghai 7
Stockholm 7
Changsha 6
Düsseldorf 6
Jinan 6
Manchester 6
Redwood City 6
Hangzhou 5
Hebei 5
Jundiaí 5
London 5
Melbourne 5
Norwalk 5
Prato 5
Atlanta 4
Brno 4
Camerino 4
Delhi 4
Falkenstein 4
Fortaleza 4
Frederick 4
Grevenbroich 4
Leawood 4
Mapo-gu 4
Totale 3.928
Nome #
Lipoxin A4 stimulates endothelial miR-126-5p expression and its transfer via microvesicles 189
Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection 173
Establishment and long-term culture of human cystic fibrosis endothelial cells 170
Mechanisms of endothelial cell dysfunction in cystic fibrosis 160
Resolvin D1 improves airway inflammation and exercise capacity in cystic fibrosis lung disease. 150
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. 145
Human Periodontal Stem Cells Release Specialized Proresolving Mediators and Carry Immunomodulatory and Prohealing Properties Regulated by Lipoxins 145
MicroRNA-181b regulates ALX/FPR2 expression and proresolution signaling in human macrophages. 142
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 135
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response 135
Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs. 131
microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense. 129
Transcriptional regulation of the human FPR2/ALX gene: evidence of a heritable genetic variant that impairs promoter activity 128
HARNESSING RESOLUTION MEDIATORS AS NOVEL THERAPEUTICS FOR CYSTIC FIBROSIS 124
Circulating endothelial progenitor cells and low-dose-aspirin-insensitive thromboxane biosynthesis in polycythemia rubra vera. 122
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. implications for aspirin 'resistance'. 122
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. 120
Epigenetic regulation of the formyl peptide receptor 2 gene 120
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. 118
Lipoxins, resolvins, and the resolution of inflammation 116
MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. 115
Lipoxin receptors 115
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 115
RESOLVIN D1 FOR TARGETING LUNG INFLAMMATION, INFECTION, AND DAMAGE IN CF 115
Resolvin D1 promotes resolution of inflammation, infection, and damage in CF 115
Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. 113
ACTIONS OF RESOLVIN D1 AND D2 IN CYSTIC FIBROSIS MRSA LUNG INFECTION AND INFLAMMATION 113
Resolvin D1 Reduces Lung Infection and Inflammation Activating Resolution in Cystic Fibrosis 111
Novel anti-inflammatory--pro-resolving mediators and their receptors. 108
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. 108
Homocysteine modulates the CD40/CD40L system 107
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". 107
Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes 106
Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis 104
Lipoxins and aspirin-triggered lipoxins in resolution of inflammation 103
Immunoresolving actions of oral resolvin D1 include selective regulation of the transcription machinery in resolution-phase mouse macrophages. 102
PRORESOLVING AND ANTIMICROBIAL BIOACTIONS OF MELANOCORTINS ON CF CELLS 98
Proresolving Lipid Mediators and Receptors in Stem Cell Biology: Concise Review 96
Resolvin E1 receptor activation signals phosphorylation and phagocytosis. 95
Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages 90
RESOLVINS, LIPOXINS, AND MARESINS IN RESOLUTION OF INFLAMMATION 89
Targeting caveolin-1 deficiency in bone marrow derived cells: A new therapeutic window for fibrotic diseases? 88
Resolvin D1 and its GPCRs in resolution circuits of inflammation. 84
Resolution of sickle cell disease–associated inflammation and tissue damage with 17R-resolvin D1 82
The Resolution Approach to Cystic Fibrosis Inflammation 82
Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen 75
Resolvin D1 and Resolvin D2 Protect Against Hypoxia/Reoxygenation Induced Lung and Kidney Damage in a Sickle Cell Mouse Model of Acute Vaso-Occlusive Crisis 74
Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer 74
PROTECTIVE ROLE OF RVD1 AND ITS RECEPTOR IN CYSTIC FIBROSIS 73
Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. 71
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury 67
Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. 66
Impaired pro-resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease 63
17R-Resolvin D1 Improves Inflammatory Cardiomyopathy in a Mouse Model of Sickle Cell Disease 61
Specialized pro-resolving lipid mediators and resolution of viral diseases 57
Roles of specialized pro-resolving lipid mediators in autophagy and inflammation 56
Resolvin D1 reduces cystic fibrosis lung disease and inflammation associated with mucus obstruction 55
Resolvins Modulate Netosis and Autoimmunity in Sickle Cell Disease 54
Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy 52
Targeting platelet activation with pro-resolving mediators: an innovative strategy to dampen lung inflammation in cystic fibrosis 50
Single cell–level pro-resolving actions of Resolvin D1 and D2 on Staphylococcus aureus lung infection and inflammation in cystic fibrosis 50
Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis 49
Development and application of a liquid chromatography–mass spectrometry method for monitoring CFTR modulators in biological fluids: a step forward in personalized CF treatment 46
Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice 44
REPURPOSING GALLIUM FOR LOCAL TREATMENT OF BACTERIAL PNEUMONIA THROUGH INHALABLE NANO-EMBEDDED MICROPARTICLES 37
Immunoregulatory mechanisms of the arachidonic acid pathway in cancer 35
Nrf2 Plays a Key Role in Erythropoiesis during Aging 34
Totale 6.578
Categoria #
all - tutte 27.243
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.243


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021297 0 0 0 0 0 67 15 14 109 46 15 31
2021/2022344 5 10 2 88 15 11 6 22 19 15 26 125
2022/2023958 72 133 61 105 88 170 49 64 146 12 32 26
2023/2024649 54 32 37 26 35 193 97 55 7 29 19 65
2024/20251.408 74 241 147 53 85 68 90 106 122 83 155 184
2025/20261.372 254 99 236 351 309 123 0 0 0 0 0 0
Totale 6.578